Compare SLNG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | IMUX |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.0M | 85.8M |
| IPO Year | N/A | N/A |
| Metric | SLNG | IMUX |
|---|---|---|
| Price | $4.51 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $10.00 | $6.00 |
| AVG Volume (30 Days) | 6.2K | ★ 1.6M |
| Earning Date | 02-24-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $72,270,000.00 | N/A |
| Revenue This Year | $7.02 | N/A |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $80.86 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.29 | $0.51 |
| 52 Week High | $8.28 | $1.39 |
| Indicator | SLNG | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 55.18 |
| Support Level | $4.33 | $0.61 |
| Resistance Level | $4.65 | $0.71 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 49.45 | 78.50 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.